AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Cash from Financing Activities of $821000.0 in Q1 2026, down 98.62% quarter-over-quarter from $59.6 million in Q1 2025, and down 98.62% on a YoY basis from $59.6 million in Q1 2025.
AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $59.7 million for Q3 2025.
- Cash from Financing Activities for Q3 2025 came in at $59.7 million, up 1120.76% year-over-year; the trailing twelve-month figure through Sep 2025 was $127.3 million (up 4026.57% YoY), and the FY2024 annual result was $5.4 million, up 164.32% from the prior year.
- Cash from Financing Activities was $821000.0 for Q1 2026 at AtaiBeckley, down from $59.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $59.6 million in Q1 2025 to a low of $821000.0 in Q1 2026.
- The 5-year median for Cash from Financing Activities is $1.8 million (2022), against an average of $32.6 million.
- Across the five-year window, Cash from Financing Activities plunged 817.68% in 2023 and surged 2279.45% in 2025, its largest moves.
- AtaiBeckley's Cash from Financing Activities stood at $1.7 million in 2021, then plunged by 153.51% to -$922000.0 in 2022, then slumped by 817.68% to -$8.5 million in 2023, then jumped by 101.82% to $154000.0 in 2024, then soared by 38694.81% to $59.7 million in 2025.
- The last three Cash from Financing Activities figures came in at $59.7 million (Q3 2025), $7.8 million (Q2 2025), and $59.6 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | 821,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 821,000.00 |
| Mar 31, 2026 | 821,000.00 |
| Sep 30, 2025 | 59.74 Mn |
| Sep 30, 2025 | 59.74 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Dec 31, 2024 | 154,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Dec 31, 2023 | -8.46 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Jun 30, 2023 | -100,000.00 |
| Jun 30, 2023 | -100,000.00 |